WO2004096236A3 - Composes de phosphonate presentant une activite immunomodulatrice - Google Patents

Composes de phosphonate presentant une activite immunomodulatrice Download PDF

Info

Publication number
WO2004096236A3
WO2004096236A3 PCT/US2004/013143 US2004013143W WO2004096236A3 WO 2004096236 A3 WO2004096236 A3 WO 2004096236A3 US 2004013143 W US2004013143 W US 2004013143W WO 2004096236 A3 WO2004096236 A3 WO 2004096236A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunomodulator
compounds
phosphonate conjugates
phosphonate
conjugates
Prior art date
Application number
PCT/US2004/013143
Other languages
English (en)
Other versions
WO2004096236A2 (fr
Inventor
Carina E Cannizzaro
James M Chen
Xiaowu Chen
Aesop Cho
Lee S Chong
Manoj Desai
Maria Fardis
Alan X Huang
Thorsten A Kirschberg
Christopher P Lee
Richard L Mackman
Peter H Nelson
Hyung-Jung Pyun
Adrian S Ray
Sundaramoorthi Swaminathan
Will Watkins
Jennifer R Zhang
Original Assignee
Gilead Sciences Inc
Carina E Cannizzaro
James M Chen
Xiaowu Chen
Aesop Cho
Lee S Chong
Manoj Desai
Maria Fardis
Alan X Huang
Thorsten A Kirschberg
Christopher P Lee
Richard L Mackman
Peter H Nelson
Hyung-Jung Pyun
Adrian S Ray
Sundaramoorthi Swaminathan
Will Watkins
Jennifer R Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ542343A priority Critical patent/NZ542343A/en
Priority to MXPA05011289A priority patent/MXPA05011289A/es
Application filed by Gilead Sciences Inc, Carina E Cannizzaro, James M Chen, Xiaowu Chen, Aesop Cho, Lee S Chong, Manoj Desai, Maria Fardis, Alan X Huang, Thorsten A Kirschberg, Christopher P Lee, Richard L Mackman, Peter H Nelson, Hyung-Jung Pyun, Adrian S Ray, Sundaramoorthi Swaminathan, Will Watkins, Jennifer R Zhang filed Critical Gilead Sciences Inc
Priority to AU2004233992A priority patent/AU2004233992A1/en
Priority to BRPI0409691-6A priority patent/BRPI0409691A/pt
Priority to EA200501678A priority patent/EA200501678A1/ru
Priority to CA002522977A priority patent/CA2522977A1/fr
Priority to JP2006513409A priority patent/JP2007536194A/ja
Priority to EP04750847A priority patent/EP1620110A2/fr
Priority to CA002542967A priority patent/CA2542967A1/fr
Priority to EP04817344A priority patent/EP1680129A2/fr
Priority to PCT/US2004/035136 priority patent/WO2005039552A2/fr
Priority to AU2004283710A priority patent/AU2004283710A1/en
Priority to JP2006536844A priority patent/JP2007520452A/ja
Publication of WO2004096236A2 publication Critical patent/WO2004096236A2/fr
Publication of WO2004096236A3 publication Critical patent/WO2004096236A3/fr
Priority to NO20055597A priority patent/NO20055597L/no
Priority to US11/406,750 priority patent/US20070027116A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés à substitution phosphonate qui présentent une activité immunomodulatrice, des compositions contenant de tels composés, des procédés thérapeutiques comprenant l'administration de tels composés, ainsi que des procédés et des produits intermédiaires utilisés pour préparer de tels composés.
PCT/US2004/013143 2003-04-25 2004-04-26 Composes de phosphonate presentant une activite immunomodulatrice WO2004096236A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP04750847A EP1620110A2 (fr) 2003-04-25 2004-04-26 Conjugues phosphonates immunomodulateurs
MXPA05011289A MXPA05011289A (es) 2003-04-25 2004-04-26 Compuestos de fosfato que tienen actividad inmunomoduladora.
AU2004233992A AU2004233992A1 (en) 2003-04-25 2004-04-26 Immunomodulator phosphonate conjugates
BRPI0409691-6A BRPI0409691A (pt) 2003-04-25 2004-04-26 compostos de fosfonato tendo atividade imuno-moduladora
EA200501678A EA200501678A1 (ru) 2003-04-25 2004-04-26 Фосфонатсодержащие иммуномодулирующие соединения (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способы модулирования или ингибирования иммунного ответа у млекопитающего
CA002522977A CA2522977A1 (fr) 2003-04-25 2004-04-26 Composes de phosphonate presentant une activite immunomodulatrice
JP2006513409A JP2007536194A (ja) 2003-04-25 2004-04-26 免疫調節性ホスホネート抱合体
NZ542343A NZ542343A (en) 2003-04-25 2004-04-26 Immunomodulator phosphonate conjugates
JP2006536844A JP2007520452A (ja) 2003-10-24 2004-10-25 ホスホネート誘導体としてのイノシン一リン酸デヒドロゲナーゼインヒビター
CA002542967A CA2542967A1 (fr) 2003-10-24 2004-10-25 Derives de phosphonate a usage therapeutique
EP04817344A EP1680129A2 (fr) 2003-10-24 2004-10-25 Inhibiteurs de l'inosine monophosphonate deshydrogenase comme derives de phosphonate
PCT/US2004/035136 WO2005039552A2 (fr) 2003-10-24 2004-10-25 Derives de phosphonate a usage therapeutique
AU2004283710A AU2004283710A1 (en) 2003-10-24 2004-10-25 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives
NO20055597A NO20055597L (no) 2003-04-25 2005-11-25 Fosfonatforbindelser med immunomodulerende aktivitet
US11/406,750 US20070027116A1 (en) 2003-10-24 2006-04-19 Therapeutic phosphonate derivatives

Applications Claiming Priority (138)

Application Number Priority Date Filing Date Title
US46558103P 2003-04-25 2003-04-25
US46553203P 2003-04-25 2003-04-25
US46537703P 2003-04-25 2003-04-25
US46553103P 2003-04-25 2003-04-25
US46548103P 2003-04-25 2003-04-25
US46542403P 2003-04-25 2003-04-25
US46538003P 2003-04-25 2003-04-25
US46584403P 2003-04-25 2003-04-25
US46537303P 2003-04-25 2003-04-25
US46557403P 2003-04-25 2003-04-25
US46543303P 2003-04-25 2003-04-25
US46542003P 2003-04-25 2003-04-25
US60/465,532 2003-04-25
US60/465,373 2003-04-25
US60/465,433 2003-04-25
US60/465,481 2003-04-25
US60/465,581 2003-04-25
US60/465,380 2003-04-25
US60/465,531 2003-04-25
US60/465,574 2003-04-25
US60/465,420 2003-04-25
US60/465,377 2003-04-25
US60/465,424 2003-04-25
US60/465,844 2003-04-25
US60/493,310 2003-07-08
US60/493,303 2003-07-08
US49330203P 2003-08-07 2003-08-07
US49330303P 2003-08-07 2003-08-07
US49330903P 2003-08-07 2003-08-07
US49331003P 2003-08-07 2003-08-07
US60/493,309 2003-08-07
US60/493,302 2003-08-07
US49553303P 2003-08-15 2003-08-15
US49541703P 2003-08-15 2003-08-15
US49566103P 2003-08-15 2003-08-15
US49541603P 2003-08-15 2003-08-15
US49539803P 2003-08-15 2003-08-15
US49539303P 2003-08-15 2003-08-15
US49542503P 2003-08-15 2003-08-15
US49553703P 2003-08-15 2003-08-15
US49545503P 2003-08-15 2003-08-15
US49542703P 2003-08-15 2003-08-15
US49561403P 2003-08-15 2003-08-15
US49552903P 2003-08-15 2003-08-15
US49545603P 2003-08-15 2003-08-15
US60/495,455 2003-08-15
US60/495,614 2003-08-15
US60/495,456 2003-08-15
US60/495,529 2003-08-15
US60/495,417 2003-08-15
US60/495,533 2003-08-15
US60/495,398 2003-08-15
US60/495,393 2003-08-15
US60/495,661 2003-08-15
US60/495,537 2003-08-15
US60/495,416 2003-08-15
US60/495,425 2003-08-15
US60/495,427 2003-08-15
US51358903P 2003-10-24 2003-10-24
US51411303P 2003-10-24 2003-10-24
US51407503P 2003-10-24 2003-10-24
US51356303P 2003-10-24 2003-10-24
US51356203P 2003-10-24 2003-10-24
US51359203P 2003-10-24 2003-10-24
US51442403P 2003-10-24 2003-10-24
US51397503P 2003-10-24 2003-10-24
US51432503P 2003-10-24 2003-10-24
US51425803P 2003-10-24 2003-10-24
US51428003P 2003-10-24 2003-10-24
US51416103P 2003-10-24 2003-10-24
US51420103P 2003-10-24 2003-10-24
US51445303P 2003-10-24 2003-10-24
US51394803P 2003-10-24 2003-10-24
US51405403P 2003-10-24 2003-10-24
US51414003P 2003-10-24 2003-10-24
US51439403P 2003-10-24 2003-10-24
US51404403P 2003-10-24 2003-10-24
US51394603P 2003-10-24 2003-10-24
US51452203P 2003-10-24 2003-10-24
US51417503P 2003-10-24 2003-10-24
US51358803P 2003-10-24 2003-10-24
US51397103P 2003-10-24 2003-10-24
US51359303P 2003-10-24 2003-10-24
US51429803P 2003-10-24 2003-10-24
US51414403P 2003-10-24 2003-10-24
US51402103P 2003-10-24 2003-10-24
US51356103P 2003-10-24 2003-10-24
US51397903P 2003-10-24 2003-10-24
US51405103P 2003-10-24 2003-10-24
US51420203P 2003-10-24 2003-10-24
US51357903P 2003-10-24 2003-10-24
US60/514,298 2003-10-24
US60/514,522 2003-10-24
US60/514,201 2003-10-24
US60/513,948 2003-10-24
US60/514,394 2003-10-24
US60/514,161 2003-10-24
US60/513,979 2003-10-24
US60/514,113 2003-10-24
US60/514,424 2003-10-24
US60/513,579 2003-10-24
US60/514,280 2003-10-24
US60/513,592 2003-10-24
US60/514,044 2003-10-24
US60/514,021 2003-10-24
US60/514,258 2003-10-24
US60/514,144 2003-10-24
US60/514,051 2003-10-24
US60/513,975 2003-10-24
US60/514,202 2003-10-24
US60/513,593 2003-10-24
US60/514,175 2003-10-24
US60/513,562 2003-10-24
US60/514,140 2003-10-24
US60/513,971 2003-10-24
US60/514,054 2003-10-24
US60/514,453 2003-10-24
US60/514,325 2003-10-24
US60/513,588 2003-10-24
US60/513,561 2003-10-24
US60/513,589 2003-10-24
US60/513,946 2003-10-24
US60/513,563 2003-10-24
US60/514,075 2003-10-24
US53193203P 2003-12-22 2003-12-22
US53196003P 2003-12-22 2003-12-22
US53223003P 2003-12-22 2003-12-22
US53194003P 2003-12-22 2003-12-22
US53216003P 2003-12-22 2003-12-22
US60/532,230 2003-12-22
US60/531,932 2003-12-22
US60/531,960 2003-12-22
US60/532,160 2003-12-22
US60/531,940 2003-12-22
US53259103P 2003-12-23 2003-12-23
US60/532,591 2003-12-23
US53600504P 2004-01-12 2004-01-12
US60/536,005 2004-12-02

Publications (2)

Publication Number Publication Date
WO2004096236A2 WO2004096236A2 (fr) 2004-11-11
WO2004096236A3 true WO2004096236A3 (fr) 2005-06-30

Family

ID=36644924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013143 WO2004096236A2 (fr) 2003-04-25 2004-04-26 Composes de phosphonate presentant une activite immunomodulatrice

Country Status (6)

Country Link
EP (1) EP1620110A2 (fr)
JP (1) JP2007254479A (fr)
EA (1) EA200501678A1 (fr)
MX (1) MXPA05011289A (fr)
NZ (1) NZ542343A (fr)
WO (1) WO2004096236A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2720618T3 (es) 2004-07-27 2019-07-23 Gilead Sciences Inc Análogos de fosfonato de compuestos de inhibidores de VIH
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
UA103329C2 (ru) 2008-07-08 2013-10-10 Гилиад Сайенсиз, Инк. Соли соединений-ингибиторов вич
EP3613750A4 (fr) * 2017-04-17 2021-01-13 Kyoto University Acide 2-amino-phosphonoalcane optiquement actif, sel d'acide 2-amino-phosphonoalcane optiquement actif, et hydrates de ceux-ci
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000988A1 (fr) * 1990-07-13 1992-01-23 Bodor Nicholas S Apport cible de medicament par l'intermediaire de derives de phosphonate
WO1996040156A1 (fr) * 1995-06-07 1996-12-19 Elizanor Biopharmaceuticals, Inc. Derives diphosphonate d'agents therapeutiques
EP0852233A1 (fr) * 1995-09-21 1998-07-08 Nippon Shinyaku Company, Limited Derives de phosphates de cyclosporine et composition medicinale
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2003059255A2 (fr) * 2001-12-21 2003-07-24 Guilford Pharmaceuticals, Inc. Procede de preparation de derives de phosphonooxymethyle d'alcool et de phenol
WO2003064383A2 (fr) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Composés contenant du phosphore et utilisations associées
WO2003090690A2 (fr) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Accumulation cellulaire d'analogues de phosphonate de composes inhibiteurs de la protease du vih

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000988A1 (fr) * 1990-07-13 1992-01-23 Bodor Nicholas S Apport cible de medicament par l'intermediaire de derives de phosphonate
WO1996040156A1 (fr) * 1995-06-07 1996-12-19 Elizanor Biopharmaceuticals, Inc. Derives diphosphonate d'agents therapeutiques
EP0852233A1 (fr) * 1995-09-21 1998-07-08 Nippon Shinyaku Company, Limited Derives de phosphates de cyclosporine et composition medicinale
WO2001013957A2 (fr) * 1999-08-24 2001-03-01 Cellgate, Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
WO2003059255A2 (fr) * 2001-12-21 2003-07-24 Guilford Pharmaceuticals, Inc. Procede de preparation de derives de phosphonooxymethyle d'alcool et de phenol
WO2003064383A2 (fr) * 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Composés contenant du phosphore et utilisations associées
WO2003090690A2 (fr) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Accumulation cellulaire d'analogues de phosphonate de composes inhibiteurs de la protease du vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIRABAYASHI H. ET AL: "Bone specific drug delivery systems", CLIN PHARMACOKINET, vol. 42, no. 15, 2003, pages 1319 - 1330, XP008037142 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs

Also Published As

Publication number Publication date
EP1620110A2 (fr) 2006-02-01
NZ542343A (en) 2009-03-31
MXPA05011289A (es) 2006-01-24
WO2004096236A2 (fr) 2004-11-11
EA200501678A1 (ru) 2006-10-27
JP2007254479A (ja) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2005002626A3 (fr) Composes de phosphonate therapeutiques
WO2004096285A3 (fr) Analogues anti-infectieux du phosphonate
WO2004096286A3 (fr) Analogues de phosphonate antiviraux
WO2004096234A3 (fr) Analogues de phosphonate inhibiteurs de kinase
TW200738741A (en) Antiviral compounds
TW200738742A (en) Antiviral compounds
PT1625126E (pt) Imidazo- e tiazolopiridinas como inibidores de cinase jak3
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2004096233A3 (fr) Analogues d'un phosphonate nucleosidique
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EP1725536B8 (fr) Derives de l'imidazoline presentant une activite antagoniste cb1
WO2008005565A3 (fr) Composés antiviraux de phosphinate
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2007014352A3 (fr) Composes antiviraux
TW200745039A (en) Isotopically substituted pantoprazole
WO2004096287A3 (fr) Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
MXPA05011294A (es) Compuestos de fosfonato anti-inflamatorios.
WO2005055943A3 (fr) Derives de la vinorelbine
WO2004096237A3 (fr) Analogues de phosphonates convenant au traitement d'affections du metabolisme
WO2004096236A3 (fr) Composes de phosphonate presentant une activite immunomodulatrice
IL165220A0 (en) Novel compounds, their use and preparation
UA92464C2 (en) Antiviral compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 542343

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 170893

Country of ref document: IL

Ref document number: 1-2005-501673

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004233992

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004233992

Country of ref document: AU

Date of ref document: 20040426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004233992

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/011289

Country of ref document: MX

Ref document number: 2522977

Country of ref document: CA

Ref document number: 2006513409

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057020254

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20048112317

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004750847

Country of ref document: EP

Ref document number: 200501678

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2004750847

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 46/2004 UNDER (30) REPLACE "60/535,160, 01 DECEMBER 2003 (01.12.2003), US" BY "60/532,160, 22 DECEMBER 2003 (22.12.2003), US"; AND REPLACE "60/514,522, 22 DECEMBER 2003 (22.12.2003), US" BY "60/514,522, 24 OCTOBER 2003 (24.10.2003), US"

ENP Entry into the national phase

Ref document number: PI0409691

Country of ref document: BR